VHL and kidney cancer: Through genetic ablation, pharmacologic inhibition, or new carbon-based proteolysis targeting chimera specifically, TBK1 was depleted/inhibited in vitro, suppressing VHL-deficient kidney cancer cell proliferation while having no effect on VHL wild-type cells.